GemVax & KAEL젬백스
082270 · KOSDAQ · ₩082270 · 젬백스
- Market cap
- ₩412B
- Enterprise value
- ₩429B
- P/E
- —
- P/B
- 2,942.4×
- Dividend yield
- 0.0%
- ROE
- −8,740.5%
- Net margin
- −14.4%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−83.5% from the high
₩8,850Today: ₩8,850 – ₩9,100₩54,900
Returns
- 1W−3.3%
- 1M−11.4%
- 3M−1.5%
- 6M−62.0%
- YTD−68.8%
- 1Y−80.5%
- Volume today
- 197,292
- 1.6× the 20-day average
- Traded today
- ₩1.8B
- Listed shares
- 45,480,587
- EPS (12 months)
- −₩269
- Earnings yield −3.0%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 49 of 100 (50 is a normal day for this stock).
- MomentumWeak-10.3% over the last month; the price is below its 20-day average.
- News impactSome5 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Futures and options
All stock futures →Futures (2026-11): 9,000
Basis −0.55% · implied rate −14.4%
Open interest 1,333 contracts
Futures and options can lose more than you put in. Figures describe the market; they are not predictions or recommendations. Paper trading only.
GemVax & KAEL stock overview
GemVax & KAEL (젬백스, KRX: 082270) is listed on KOSDAQ, in the Machinery sector. Gemvax & Kael's business is split into two segments. Its shares closed at ₩9,050 on Oct 29, 2026, up 0.11% on the day, giving it a market value of ₩412B.
Key facts
- Market cap
- ₩412B
- Sector
- Machinery
- Latest price change
- +0.11%
- As of
- Oct 29, 2026
- Main business
- Gemvax & Kael's business is split into two segments.
Quick answers about GemVax & KAEL
- What does GemVax & KAEL do?
- Gemvax & Kael's business is split into two segments. Its environmental pollution control segment manufactures and sells Chemical Air Filters and related filter media, used in semiconductor and display manufacturing cleanrooms to remove airborne molecular contamination, and also provides clean-room air quality and air pollution/odor control equipment. Its bio segment develops peptide-based drugs derived from telomerase technology, centered on its lead candidate GV1001, which is in clinical trials for Alzheimer's disease and progressive supranuclear palsy, with a license agreement covering GV1001 for progressive supranuclear palsy in South Korea, Japan, India and Indonesia.
- What is the market cap of GemVax & KAEL?
- The market capitalisation of GemVax & KAEL was ₩412B at the close on Oct 29, 2026.
- Who are the largest shareholders of GemVax & KAEL?
- According to the latest official filings, the largest reported holders are Gem & Company (24.94%, as of Oct 26, 2026); National Pension Service (2.55%, as of Dec 31, 2025); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (1.18%, as of Jul 31, 2026).
- When is the next earnings report from GemVax & KAEL?
- Korean companies rarely announce results dates in advance. Based on when GemVax & KAEL filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own GemVax & KAEL?
- Yes. The National Pension Service held 2.55% of GemVax & KAEL shares as of Dec 31, 2025.
Company profile
Gemvax & Kael's business is split into two segments. Its environmental pollution control segment manufactures and sells Chemical Air Filters and related filter media, used in semiconductor and display manufacturing cleanrooms to remove airborne molecular contamination, and also provides clean-room air quality and air pollution/odor control equipment. Its bio segment develops peptide-based drugs derived from telomerase technology, centered on its lead candidate GV1001, which is in clinical trials for Alzheimer's disease and progressive supranuclear palsy, with a license agreement covering GV1001 for progressive supranuclear palsy in South Korea, Japan, India and Indonesia.
Written by AI from the company's latest annual report.
- Korean name
- 젬백스
- Sector
- Machinery
- Themes
- Biotech (new drugs)
- CEO
- 김기호, 이석준
- Founded
- Mar 1998
- Listed
- Jun 2005
- Listed shares
- 45,480,587
- Fiscal year ends
- Month 12
- Website
- www.kael.co.kr
Similar companies
- Doosan Enerbility034020 · ₩36T₩56,700−7.65%
- Hanmi Semiconductor042700 · ₩19T₩196,900−3.24%
- Jusung Engineering036930 · ₩8.2T₩177,000−4.58%
- Rainbow Robotics277810 · ₩7.3T₩378,000−6.55%
- EO Technics039030 · ₩5.1T₩415,000−0.84%
- Doosan Bobcat241560 · ₩4.7T₩49,150−0.61%
- Wonik IPS240810 · ₩4.7T₩95,900−3.62%
- PSK Holdings031980 · ₩4.2T₩194,200+0.62%
Recent filings
See all- Decision on Increase in Short-Term BorrowingsOct 30, 2026
- Merger Completion Report (Asset Acquisition and Transfer)Oct 30, 2026
- [Amended Filing] Major Matters Report (Decision on Acquisition of Tangible Assets)Oct 30, 2026
- 5%+ holding reportOct 26, 2026
- Amended: Change of largest shareholderOct 19, 2026
Titles in Korean until English translations are added.
Also known as: GemVax & KAEL / 젬백스 / 082270 / KRX:082270
Source: KRX statistical information